MedPath

Nicotinamide riboside

Generic Name
Nicotinamide riboside
Drug Type
Small Molecule
Chemical Formula
C11H15N2O5
CAS Number
1341-23-7
Unique Ingredient Identifier
0I8H2M0L7N
Background

Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).

Clinical Trials
Related News

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Phase 2
Recruiting
Conditions
Kidney Disease
Vascular Diseases
Blood Pressure
Oxidative Stress
Interventions
First Posted Date
2019-08-01
Last Posted Date
2024-04-10
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
118
Registration Number
NCT04040959
Locations
🇺🇸

UColorado, Aurora, Colorado, United States

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

Phase 2
Completed
Conditions
Small Fiber Neuropathy
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2019-04-11
Last Posted Date
2024-06-12
Lead Sponsor
Johns Hopkins University
Target Recruit Count
45
Registration Number
NCT03912220
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

Phase 2
Recruiting
Conditions
Hypertension
Aging
Interventions
Other: Placebo
First Posted Date
2019-01-30
Last Posted Date
2025-02-21
Lead Sponsor
Douglas Seals
Target Recruit Count
118
Registration Number
NCT03821623
Locations
🇺🇸

Integrative Physiology of Aging Laboratory, Boulder, Colorado, United States

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

Phase 3
Completed
Conditions
Peripheral Artery Disease
Interventions
Other: Placebo
First Posted Date
2018-11-16
Last Posted Date
2025-01-14
Lead Sponsor
Northwestern University
Target Recruit Count
90
Registration Number
NCT03743636
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

Nicotinamide Riboside for Diabetic Neuropathy

Phase 1
Suspended
Conditions
Diabetic Neuropathy Peripheral
Interventions
Drug: Placebo
First Posted Date
2018-09-26
Last Posted Date
2022-04-05
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
54
Registration Number
NCT03685253
Locations
🇺🇸

University of Maryland, Baltimore, Maryland, United States

NR in Chemo-induced Peripheral Neuropathy

Phase 2
Terminated
Conditions
Chemotherapy-induced Peripheral Neuropathy
Breast Cancer Metastatic
Platinum-resistant Recurrent Ovarian Cancer
Head and Neck Cancer Stage IV
Endometrial Cancer Stage IV
Interventions
First Posted Date
2018-08-22
Last Posted Date
2023-04-12
Lead Sponsor
Donna Hammond, PhD
Target Recruit Count
5
Registration Number
NCT03642990
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

🇺🇸

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics

Phase 4
Terminated
Conditions
Healthy
Interventions
First Posted Date
2017-05-12
Last Posted Date
2024-03-05
Lead Sponsor
Mclean Hospital
Target Recruit Count
11
Registration Number
NCT03151707
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy